MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib

The third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI–treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its un...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Nishiyama, Akihiro, Takeuchi, Shinji, Adachi, Yuta, Otani, Sakiko, Tanimoto, Azusa, Sasaki, Motoko, Matsumoto, Shingo, Goto, Koichi, Yano, Seiji
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Drug Discovery and Delivery
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540985/
https://ncbi.nlm.nih.gov/pubmed/32735723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14593
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados